Tsakiris D A, Tschöpl M, Wolf F, Labs K H, Jäger K A, Marbet G A
Haemostasis Laboratory DCL, University Hospital Basel, Switzerland.
Blood Coagul Fibrinolysis. 2000 Mar;11(2):165-73.
We tested the hypothesis whether circulating oncostatin-M (OSM), a cytokine that in vitro promotes fibrinogen biosynthesis and smooth muscle cell proliferation, or soluble CD40 ligand (CD40L; CD154), a leukocyte and platelet surface marker that stimulates endothelial cells, were associated: (a) with fibrinogen and other soluble cell adhesion molecules, such as P-selectin, vascular cell adhesion molecule-1 (VCAM-1), intercellular cell adhesion molecule-1 and platelet-endothelial cell adhesion molecule-1; or (b) with restenosis and platelet activation in 71 patients with peripheral arterial occlusive disease undergoing peripheral angioplasty (PTA). Platelet membrane activation markers (CD62P, CD63, activated GPIIb/IIIa) were immunologically measured at 0, 1, 24 and 48 h, and 3 and 6 months after PTA. Soluble cell adhesion molecules, endothelial markers and various hemostatic variables were measured before PTA. Of the patients, 42.3% developed restenosis within 6 months, defined as a >50% reduction of the lumen at the site of balloon dilatation. Soluble CD40L was not higher in the restenosis group. Interestingly, patients with high CD40L showed significantly higher soluble VCAM-1 (P < 0.01) and thrombomodulin (P < 0.01), as well as trends for higher soluble P- and E-selectin. Platelet activation was found uniformly increased mostly at 1 and 24 h, as well as at 3 and 6 months. OSM was measurable in 53.5% (6.9 +/- 9.4 pg/ml) of the patients and undetectable in the others. No differences in the rate of restenosis was found in these two groups, which did not differ with respect to fibrinogen (3.14 +/- 1.00 versus 3.21 +/- 0.70 g/l), or the other parameters. In conclusion, soluble CD40L is associated with higher endothelial biological markers that might implicate its involvement in endothelial activation. Platelet activation, probably intermittent, might play a significant role through the expression of CD40L as a source of activation signals to the endothelial cells. Free circulating OSM does not seem to correlate directly with fibrinogen or with other acute phase reaction proteins, the synthesis of which it could influence in vitro. This might well not mean, however, that OSM lacks this activity in vivo.
循环肿瘤抑制素-M(OSM),一种在体外可促进纤维蛋白原生物合成和平滑肌细胞增殖的细胞因子,或可溶性CD40配体(CD40L;CD154),一种刺激内皮细胞的白细胞和血小板表面标志物,是否与以下因素相关:(a)纤维蛋白原和其他可溶性细胞黏附分子,如P-选择素、血管细胞黏附分子-1(VCAM-1)、细胞间黏附分子-1和血小板-内皮细胞黏附分子-1;或(b)71例接受外周血管成形术(PTA)的外周动脉闭塞性疾病患者的再狭窄和血小板活化情况。在PTA后0、1、24和48小时以及3和6个月时,通过免疫方法检测血小板膜活化标志物(CD62P、CD63、活化的GPIIb/IIIa)。在PTA前检测可溶性细胞黏附分子、内皮标志物和各种止血变量。42.3%的患者在6个月内发生再狭窄,定义为球囊扩张部位管腔缩小>50%。再狭窄组中可溶性CD40L并不更高。有趣的是,CD40L水平高的患者可溶性VCAM-1(P<0.01)和血栓调节蛋白(P<0.01)显著更高,可溶性P-选择素和E-选择素也有升高趋势。发现血小板活化在1和24小时以及3和6个月时普遍增加。53.5%(6.9±9.4 pg/ml)患者可检测到OSM,其他患者未检测到。这两组在再狭窄发生率方面无差异,在纤维蛋白原(3.14±1.00与3.21±0.70 g/l)或其他参数方面也无差异。总之,可溶性CD40L与更高的内皮生物学标志物相关,这可能意味着它参与了内皮细胞活化。血小板活化可能是间歇性的,可能通过作为内皮细胞活化信号来源的CD40L表达发挥重要作用。游离循环的OSM似乎与纤维蛋白原或其他急性期反应蛋白无直接关联,尽管它在体外可影响这些蛋白的合成。然而,这很可能并不意味着OSM在体内缺乏这种活性。